Melanocyte

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma

Retrieved on: 
Thursday, February 22, 2024

DermBiont currently anticipates that data will be available in Q3 2024.

Key Points: 
  • DermBiont currently anticipates that data will be available in Q3 2024.
  • SKs: DermBiont expects to report data from its CT-213 Phase 2b clinical trial of SM-020 gel 1.0% in Q3 2024.
  • BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024.
  • Melasma: DermBiont anticipates enrolling the first patient in its randomized, observer-blinded, vehicle-controlled CT-214 Phase 2b trial of SM-030 in 138 subjects with melasma in Q2 2024.

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Retrieved on: 
Wednesday, January 10, 2024

The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.

Key Points: 
  • The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.
  • Positive clinical data from the Phase 1b trial were announced in October 2023.
  • One lesion, selected for treatment with VYN201, had skin tissue biopsies taken prior to first application of VYN201 and after 8 weeks of treatment.
  • “We are encouraged by these new biomarker data from the Phase 1b trial for VYN201, building on our recently announced positive clinical results,” said David Domzalski, President and CEO of VYNE.

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

Retrieved on: 
Wednesday, October 11, 2023

These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.

Key Points: 
  • These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.
  • Opzelura is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
  • The overall prevalence of the condition is estimated to be approximately 2-3 million2, with the majority of patients (approximately 85%) suffering from nonsegmental vitiligo3.
  • Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 304.

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Retrieved on: 
Wednesday, October 11, 2023

Incyte (Nasdaq:INCY) today announced new 52-week data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new 52-week data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.
  • “These 52-week results further support earlier data and reinforce the efficacy profile and potential of povorcitinib as an oral treatment for patients with extensive nonsegmental vitiligo,” said Kurt Brown, M.D., Vice President and Povorcitinib Global Program Head, Incyte.
  • “At Incyte, we are deeply committed to addressing unmet needs in the vitiligo community and understanding how this disease can affect patients’ lives.
  • Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 304.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
Wednesday, August 23, 2023

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
Wednesday, August 23, 2023

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Zebrafish share skin-deep similarities with people, making them helpful models to study skin conditions like vitiligo and melanoma

Retrieved on: 
Monday, July 10, 2023

They do this by synthesizing melanins, which are pigments sent to other skin cells to shield them from harmful ultraviolet light.

Key Points: 
  • They do this by synthesizing melanins, which are pigments sent to other skin cells to shield them from harmful ultraviolet light.
  • A lack of functioning melanocytes causes a wide range of skin conditions, including skin cancer and vitiligo, an autoimmune condition in which the body attacks melanocytes and causes patches of depigmented skin.
  • Difficulties growing human melanocytes in cell cultures have led researchers like me to use alternative models to study them.

What zebrafish and people have in common

    • Melanocytes in zebrafish are similar in many ways to those in people.
    • Unlike melanocytes in mouse or human skin, zebrafish melanocytes are externally visible in their dark stripes and spotted scales.
    • Importantly, researchers can manipulate and perform experiments on zebrafish melanocytes in ways that are unethical or not feasible to do with people.

Diversity of melanocyte stem cells

    • It’s also relevant to age-related conditions like hair graying, in which melanocyte stem cells either die or become dormant and no longer produce the mature melanocytes that give hair its color.
    • Since melanocyte stem cells in zebrafish are externally visible, we tracked these cells in real time to see how they divided and matured.
    • Additionally, we measured which genes were expressed in individual melanocyte stem cells and their descendants during regeneration.
    • We found that dying melanocytes trigger this regenerative process by sending the signal for melanocyte stem cells – cells that can give rise to new melanocytes – to activate.

From fish to people

    • When we examined cells taken from the fluid within a blister in human skin, we found cells that look remarkably similar to zebrafish melanocyte stem cells.
    • We are planning to see whether these human cells are activated in skin regeneration to make new melanocytes, which would confirm their identity as melanocyte stem cells.

Nature Publication Reveals Cutting-Edge Advancements in Understanding Hair Growth

Retrieved on: 
Wednesday, June 21, 2023

SAN DIEGO, June 21, 2023 /PRNewswire/ -- Amplifica Holdings Group, Inc. ("Amplifica"), a privately held, clinical-stage biopharmaceutical company announced that research into a naturally occurring process for hair growth that may lead to the treatment of hair loss was published in the journal Nature. Nature is an international journal publishing original peer-reviewed research that is of broad significance in all fields of science and technology. Work on the research paper entitled "Signaling by senescent melanocytes hyperactivates hair growth" was led by Amplifica's co-founder Maksim Plikus, Ph.D.

Key Points: 
  • "The publication of these original findings in the leading interdisciplinary journal Nature further validates Amplifica's pipeline compounds and its plans to develop novel solutions to treat hair loss."
  • Researchers tracked the activity of hair follicle stem cells in mole skin over time and found that the excessive hair growth in these mice was driven by a shorter than typical time frame between consecutive hair growth cycles.
  • To further test the hair growth effects of osteopontin, collaborators at Amplifica administered a dose of osteopontin to human hair follicles in skin grafts.
  • Results from this extensive research validate the potential for hair growth stimulation with compounds that are under development by Amplifica.

Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

Retrieved on: 
Thursday, April 20, 2023

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has granted a marketing authorization for Opzelura® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has granted a marketing authorization for Opzelura® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
  • “The approval of Opzelura by the European Commission represents a significant advancement for people living with non-segmental vitiligo with facial involvement who, until now, had no approved medical treatment to address repigmentation,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • Pivotal Phase 3 data supporting the European Commission decision were also published in The New England Journal of Medicine.
  • Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 305.